We Claim:

1. A synergistic combination comprising an antibody specific for CD19 wherein said antibody comprises an HCDR1 region of sequence SYVMH (SEQ ID NO: 1), an HCDR2 region of sequence NPYNDG (SEQ ID NO: 2), an HCDR3 region of sequence GTYYYGTRVFDY (SEQ ID NO: 3), an LCDR1 region of sequence RSSKSLQNVNGNTYLY (SEQ ID NO: 4), an LCDR2 region of sequence RMSNLNS (SEQ ID NO: 5), and an LCDR3 region of sequence MQHLEYPIT (SEQ ID NO: 6) and a phosphoinositide 3-kinase inhibitor for use in the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia.

2. A combination according to claim 2, wherein the antibody comprises a variable heavy chain of the sequence
EVQLVESGGGLVKPGGSLKLSCAASGYTFTSYVMHWVRQAPGKGLEWIGYINPY
NDGTKYNEKFQGRVTISSDKSISTAYMELSSLRSEDTAMYYCARGTYYYGTRVFDYWG
QGTLVTVSS (SEQ ID NO: 10) and a variable light chain of the sequence
DIVMTQSPATLSLSPGERATLSCRSSKSLQNVNGNTYLYWFQQKPGQSPQLLIYR
MSNLNSGVPDRFSGSGSGTEFTLTISSLEPEDFAVYYCMQHLEYPITFGAGTKLEIK (SEQ ID NO: 11).

3. A combination according to any one of the preceding claims, wherein the antibody comprises a heavy chain constant domain of the sequence
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSL
SSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPDVFLFPPKPK
DTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQD
WLNGKEYKCKVSNKALPAPEEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIA
VEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSL
SLSPGK (SEQ ID NO: 12).

4. A combination according to any one of the preceding claims, wherein the antibody comprises a light chain constant domain of the sequence
RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKD
STYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 13).

5. A combination according to any one of the preceding claims, wherein said antibody specific for CD19 and said phosphoinositide 3-kinase inhibitor are administered separately.

6. A combination according to claim 5, wherein said antibody specific for CD19 and said phosphoinositide 3-kinase inhibitor are administered separately physically.

7. A combination according to claim 5, wherein said antibody specific for CD19 and said phosphoinositide 3-kinase inhibitor are administered separately in time.

8. A combination according to any one of claims 1-4, wherein said antibody specific for CD19 and said phosphoinositide 3-kinase inhibitor are administered together.

9. A combination according to any one of the preceding claims, wherein said phosphoinositide 3-kinase inhibitor is administered prior to administration of the antibody specific for CD19.

10. A combination according to any one of the preceding claims, wherein said phosphoinositide 3-kinase inhibitor is administered after administration of the antibody specific for CD19.

11. A combination according to any one of claims 1-4, wherein said phosphoinositide 3-kinase inhibitor and the antibody specific for CD19 are administered simultaneously.

12. A combination according to any one of the preceding claims, where said said phosphoinositide 3-kinase inhibitor is Idelalisib.

13. A combination according to any one of the preceding claims for use in the treatment of non-Hodgkin's lymphoma, wherein the non-Hodgkin's lymphoma is selected from the group consisting of follicular lymphoma, small lymphocytic lymphoma, mucosa-associated lymphoid tissue, marginal zone, diffuse large B cell, Burkitt's, and mantle cell.

14. A combination according to any one of the preceding claims for use in the treatment of chronic lymphocytic leukemia.

15. A combination according to any one of the preceding claims for use in the treatment of acute lymphoblastic leukemia.